


A Vaginal Ring Containing Dapivirine for HIV-1 PrEP
MTN-020-ASPIRE

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP

MTN-020-ASPIRE Study: Background


- **Background:** Randomized, double-blind, phase 3, placebo-controlled trial of a dapivirine-containing vaginal ring changed every 4 weeks as compared to a placebo ring for HIV-1 prevention for women at multiple sites in Malawi, South Africa, Uganda and Zimbabwe
- **Inclusion Criteria** (n = 2,629 enrolled)
 - 18-45 years of age
 - HIV seronegative
 - Sexually active
 - Nonpregnant
- **Treatment Arms**
 - Dapivirine 25 mg vaginal ring, changed monthly
 - Placebo vaginal ring, changed monthly



A Vaginal Ring Containing Dapivirine for HIV-1 PrEP

MTN-020-ASPIRE Study: Results

Number of New HIV Infections (All Sites)




Source: Baeten JM, et al. N Engl J Med. 2016;375:2121-32.

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP

MTN-020-ASPIRE Study: Results


Number of New HIV Infections (All Sites): Risk Reduction Compared with Placebo



Source: Baeten JM, et al. N Engl J Med. 2016;375:2121-32.

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP MTN-020-ASPIRE Study: Results

Number of New HIV Infections (Excluding 2 Study Sites with Poor Retention)




Source: Baeten JM, et al. N Engl J Med. 2016;375:2121-32.

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP

MTN-020-ASPIRE Study: Results

Number of New HIV Infections (Excluding 2 Study Sites with Poor Retention): Risk Reduction




Source: Baeten JM, et al. N Engl J Med. 2016;375:2121-32.

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP

MTN-020-ASPIRE Study: Results


Incidence Rate for New HIV Infections



A Vaginal Ring Containing Dapivirine for HIV-1 PrEP


MTN-020-ASPIRE Study: Results

Incidence Rate for New HIV Infections: Risk Reduction Compared with Placebo



A Vaginal Ring Containing Dapivirine for HIV-1 PrEP MTN-020-ASPIRE Study: Results

Relative Reduction in HIV Infections, by Age Group



A Vaginal Ring Containing Dapivirine for HIV-1 PrEP

MTN-020-ASPIRE Study: Results

Reduction in HIV Incidence by Age Groups in ASPIRE	
	HIV Protection (Reduction in Incidence Comparing Dapivirine Ring to Placebo)
Subgroup Analysis	
<25 years of age	10%
>25 years of age	*61%
Post-hoc Analysis	
18-21 years of age	27%
21-27 years of age	*56%
27-45 years of age	*51%
*Improved HIV protection in older age groups correlated with increased markers of adherence	

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP

MTN-020-ASPIRE Study: Conclusions

Conclusions: “A monthly vaginal ring containing dapivirine reduced the risk of HIV-1 infection among African women, with increased efficacy in subgroups with evidence of increased adherence.”

Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling \$1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

